AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19967423
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered once a week (QW)
Trial: 19967423
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered every 2 weeks (Q2W)
Trial: 18929239
Drug: No anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulation therapy (no-heparin arm)
Trial: 18929239
Drug: Standard anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulation regimen (control arm: 70 to 100 UI/kg unfractionated heparin)
Trial: 11806881
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral loratadine, once daily for three days
Trial: 10075338
Drug: Fe group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe group (60 mg Fe and 250 microg folate)
Trial: 10075338
Drug: Fe+Zn group
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe+Zn group (60 mg Fe, 250 microg folate, and 15 mg Zn)
Trial: 8613581
Drug: Daily toothbrushing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily toothbrushing programme with fluoride dentifrice
Trial: 8613581
Drug: Daily toothbrushing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily toothbrushing programme with fluoride dentifrice plus weekly 0.2% fluoride rinse
Trial: 31479947
Drug: Adjuvant imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant imatinib treatment
Trial: 10390201
Drug: Aminoglycosides administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides administered twice daily
Trial: 10390201
Drug: Aminoglycosides administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycosides administered once daily
Trial: 1672278
Drug: Prophylactic somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic somatostatin infusion before, during, and after the procedure
Trial: 27748055
Drug: Fulranumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab (1 mg every 4 weeks)
Trial: 27748055
Drug: Fulranumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab (3 mg every 4 weeks)
Trial: 27748055
Drug: Fulranumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab (10 mg every 8 weeks)
Trial: 27748055
Drug: Fulranumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab (all doses)
Trial: 23688527
Drug: PCV13 (follow-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (follow-on dose after 1 year)
Trial: 11503007
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg twice daily (1 day before treatment and 3 days of concomitant administration)
Trial: 11503007
Drug: Rifampin 300
RxNorm normalized name: rifampin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 300 mg twice daily (3 days before treatment and 3 days of concomitant administration)
Trial: 8007702
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil - CMF)
Trial: 3527011
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of almitrine bismesylate twice daily
Trial: 3527011
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of almitrine bismesylate twice daily
Trial: 30301127
Drug: Flavanol-rich cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich cocoa (2.5 g/day for 12 weeks)
Trial: 30301127
Drug: Cocoa-free capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa-free capsules (placebo)
Trial: 28988541
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg plus PQP 640 mg
Trial: 28988541
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg plus PQP 960 mg
Trial: 28988541
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg plus PQP 1440 mg
Trial: 28988541
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg plus PQP (all doses)
Trial: 28988541
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg plus PQP (in African population)
Trial: 28988541
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg plus PQP (in Vietnam)
Trial: 28988541
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg plus PQP
Trial: 16531905
Drug: CLA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA (5 g.d(‐1))
Trial: 12534358
Drug: 250 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 microg (5000 IU) r‐hCG subcutaneously twice each week for 3 months (n=20)
Trial: 12534358
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 3 months (n=20)
Trial: 9484091
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser treatment (Group A) with varying power levels (0.8 W, 1.0 W, 1.2 W, 1.5 W)
Trial: 9484091
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser treatment at different power levels
Trial: 6348378
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of methylprednisolone (MP)
Trial: 6348378
Drug: Low-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose regimen of methylprednisolone (MP)
Trial: 31575537
Drug: Integrated GP
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated GP care for persistent physical symptoms; details on dosage and duration not available.
Trial: 31575537
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (waiting list); details on dosage and duration not available.
Trial: 27406589
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose bevacizumab (5 mg/kg) plus lomustine (90 mg/m²)
Trial: 27406589
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose bevacizumab (10 mg/kg)
Trial: 11852292
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg/d for 1 week, then 20 mg/d) in depressed patients (n = 18) and half of the nondepressed subgroup (n = 14)
Trial: 11852292
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg/d for 1 week, then 20 mg/d)
Trial: 9787148
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) with autologous stem cell support (early HDT group, n = 91)
Trial: 9787148
Drug: Conventional-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose chemotherapy (CCT) regimen (late HDT group, n = 94)
Trial: 9787148
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) with autologous stem cell support (early HDT group)
Trial: 9787148
Drug: Conventional-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose chemotherapy (CCT) regimen (late HDT group)
Trial: 7674688
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers and beta-blockers for rate control
Trial: 7674688
Drug: Low-dose anticoagulation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anticoagulation therapy
Trial: 7674688
Drug: Amiodarone in
RxNorm normalized name: amiodarone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone in low doses
Trial: 581950
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg digoxin orally
Trial: 581950
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg digoxin i.v.
Trial: 26666738
Drug: Intraoperative infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative infusion of branched-chain amino acids (BCAA) solution (N = 20)
Trial: 26666738
Drug: Intraoperative infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative infusion of amino acids (AA) solution (N = 21)
Trial: 21324747
Drug: Conventional intracytoplasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intracytoplasmic sperm injection (ICSI)
Trial: 21324747
Drug: Intracytoplasmic morphologically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic morphologically selected sperm injection (IMSI) in severe male factor patients
Trial: 21324747
Drug: Conventional intracytoplasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intracytoplasmic sperm injection (ICSI) in severe male factor patients
Trial: 18292452
Drug: Preoperative PVB
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative PVB with 20 mL of ropivacaine 0.5%
Trial: 18292452
Drug: Continuous ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ropivacaine 0.5% infusion (CRI) at a 2 mL/h rate for 24 h
Trial: 14637276
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment supplemented with antioxidants for 12 weeks
Trial: 7956400
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with etoposide (100 mg/m2), cisplatin (25 mg/m2), ifosfamide (1.5 g/m2), and mesna (1.8 g/m2) for 4 days, 3 cycles every 21 days
Trial: 3314173
Drug: Non-retard cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-retard cimetidine preparation
Trial: 2179096
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol (dosage to reduce resting pulse rate by 25%)
Trial: 2179096
Drug: Long-term injection
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term injection sclerotherapy
Trial: 1097148
Drug: THC 20
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC 20 mg + CBN 40 mg
Trial: 1097148
Drug: THC 20
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC 20 mg + CBD 40 mg
Trial: 1097148
Drug: THC 20
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC 20 mg + Placebo
Trial: 30767409
Drug: 125 g
RxNorm normalized name: ASIAN GINSENG 0.125 g ORAL TABLET [Singiso]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 g of frozen red raspberries (RR-125)
Trial: 30767409
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g of frozen red raspberries (RR-250)
Trial: 30767409
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of frozen red raspberries (Control)
Trial: 25832312
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg every 2 weeks and CZP 400 mg every 4 weeks
Trial: 21832988
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg) + Active cognitive bias training
Trial: 21832988
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg) + Control cognitive bias training
Trial: 19627023
Drug: Granisetron 2
RxNorm normalized name: granisetron 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 2 mg plus Lidocaine
Trial: 19627023
Drug: Granisetron/lidocaine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron/lidocaine combination
Trial: 1676524
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg remoxipride
Trial: 10525751
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sulpiride
Trial: 28492790
Drug: rhBNP (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBNP (0.005 µg kg‐1 min‐1 for 72 hours)
Trial: 22082239
Drug: Brief lifestyle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief lifestyle counseling (quarterly PCP visits + brief monthly sessions with lifestyle coaches)
Trial: 22082239
Drug: Enhanced brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced brief lifestyle counseling (same as brief lifestyle counseling + meal replacements or weight-loss medication)
Trial: 16501036
Drug: Intranasal E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2/NETA [175 microg/275 microg]
Trial: 16501036
Drug: Oral E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2/NETA [1 mg/0.5 mg]
Trial: 9095401
Drug: Vigabatrin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (150 mg/kg per day)
Trial: 9095401
Drug: Hydrocortisone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (15 mg/kg per day)
Trial: 1311650
Drug: Subpressor dose
RxNorm normalized name: Suppressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min)
Trial: 1311650
Drug: Subpressor dose
RxNorm normalized name: Suppressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min) during handgrip exercise
Trial: 1311650
Drug: Pressor dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min)
Trial: 1311650
Drug: Pressor dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min) during isometric exercise
Trial: 4017672
Drug: Theophylline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (4 mg/kg twice daily for three days)
Trial: 31186395
Drug: DynaCT+DSA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DynaCT+DSA treatment group (27 cases)
Trial: 31186395
Drug: DSA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSA treatment group (30 cases)
Trial: 31186395
Drug: DynaCT+DSA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DynaCT+DSA treatment group
Trial: 31186395
Drug: DSA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSA treatment group
Trial: 12910523
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and paclitaxel (C/P) for 4 cycles (AUC of 6 for carboplatin and 200 mg/m2 for paclitaxel every 21 days)
Trial: 9259219
Drug: Short cognitive
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short cognitive behavioural group therapy programme focused on patient education and stress relaxation.
Trial: 8318322
Drug: Extradural clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural clonidine 450 micrograms plus oral yohimbine 16 mg
Trial: 26846934
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (2 sessions per week for 6 weeks)
Trial: 26846934
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (hip arthroscopy and physical therapy)
Trial: 16639677
Drug: Heparin-coated ECC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated ECC circuits (group A)
Trial: 14583417
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 alfalfa capsules per day)
Trial: 14583417
Drug: Low-dose kelp
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose kelp (2 kelp capsules and 2 alfalfa capsules per day)
Trial: 14583417
Drug: High-dose kelp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose kelp (4 kelp capsules per day)
Trial: 10981244
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors in hypertensive patients
Trial: 10981244
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors in normotensive patients
Trial: 10981244
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors usage over time
Trial: 10981244
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors in patients with adverse renal outcomes
Trial: 7643882
Drug: Heparin (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (10,000 IU bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Trial: 7643882
Drug: Intravenous hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Trial: 7643882
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and subcutaneous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous hirudin twice daily for three days)
Trial: 7643882
Drug: Hirudin (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (combined group of intravenous and subcutaneous)
Trial: 7643882
Drug: Intravenous hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hirudin
Trial: 31124299
Drug: iGlarLixi (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi (insulin glargine 100 U and lixisenatide)
Trial: 20831368
Drug: Locally delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally delivered doxycycline (8.8% doxycycline gel) as an adjunct to mechanical debridement
Trial: 3755608
Drug: CQP201-403 (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQP201-403 (0.025 mg)
Trial: 20974324
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Trial: 20974324
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Trial: 20974324
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of Clopidogrel bisulfate
Trial: 20974324
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of Clopidogrel bisulfate
Trial: 8777116
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered intravenously over 15 seconds to premedicated children with midazolam
Trial: 8777116
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered intravenously over 15 seconds to unpremedicated children
Trial: 1497159
Drug: Minidose succinylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minidose succinylcholine (0.1 mg/kg) IV
Trial: 1497159
Drug: Pancuronium (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.03 mg/kg) IV
Trial: 22587345
Drug: Glimepiride 1-2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1-2 mg
Trial: 16043939
Drug: Regimen 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 1: All antihypertensive agents given once a day in the morning
Trial: 16043939
Drug: Regimen 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 2: All antihypertensive agents given in the morning, except the CCB which was given at 4:00 pm
Trial: 11812685
Drug: Weight-based aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight-based aprotinin dosing schedule
Trial: 10520404
Drug: EE/CPA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/CPA (2 mg cyproterone acetate and 0.035 mg ethinyloestradiol)
Trial: 1936012
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 40 mg t.i.d.